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The management and outcomes of stage IV colorectal
cancer have changed signiﬁcantly over the past 5–10
years. The advent of relatively effective, multimodal-
ity regimens of 5-fluorouracil and leucovorin com-
bined with cytotoxic agents (e.g., oxaliplatin or
irinotecan) and targeted therapies (e.g., bevacizumab
or cetuximab) has resulted in unprecedented rates of
both tumor response and patient survival.1,2 Simul-
taneously the indications for surgery in the manage-
ment of hepatic and pulmonary metastases from
colorectal cancer continue to expand. However, for
patients with carcinomatosis from colorectal cancer,
the view remains generally nihilistic for a number of
reasons. First, the historical life expectancy of patients
with colorectal carcinomatosis was a dismal 6–7
months.3 Second, surgery has traditionally not been
shown to play any signiﬁcant role other than selective
palliation. Third, despite the overall results of the
more efﬁcacious chemotherapy regimens, the actual
beneﬁt to patients with carcinomatosis has yet to be
determined. Consequently, while evidence-based
guidelines recommending neoadjuvant chemotherapy
followed by surgery for the management of patients
with hepatic and pulmonary metastases are readily
available, there are no management guidelines for
patients with carcinomatosis.
Despite this daunting backdrop, signiﬁcant eﬀorts
are being made to improve the outcome of patients
with carcinomatosis. One such eﬀort is the use of a
combined treatment approach involving cytoreductive
surgery (CRS) and perioperative intraperitoneal che-
motherapy (PIC). Currently, this approach is gaining
recognition as a treatment option for a variety of
peritoneal surface-based malignancies. Signiﬁcant
improvements in disease-free and overall survival from
CRS and PIC have been demonstrated in patients with
peritoneal dissemination of appendiceal and ovarian
cancers and diﬀuse malignant peritoneal mesotheli-
oma.4–6 In fact, CRS and PIC are considered by many
to be the standard of care for select patients with
peritoneal-based disease from these malignancies.7,8
CRS and PIC have also been used in the treatment of
carcinomatosis from colorectal cancer with some cen-
ters publishing 5-year survival rates of 30% or high-
er.9–12 For such a historically hopeless clinical
situation, these results seem almost miraculous. Con-
sequently, and despite a paucity of high-level evidence,
a consensus statement has been published advocating
the use of CRS and PIC in select colorectal patients
with carcinomatosis.13,14
In ‘‘Failure Analysis of Recurrent Disease Follow-
ing Complete Cytoreduction and Perioperative Intra-
peritoneal Chemotherapy in Patients with Peritoneal
Carcinomatosis from Colorectal Cancer,’’ Bijelic et al.
15 are the ﬁrst to analyze the anatomic distribution,
timing, and outcomes of recurrent peritoneal disease
after complete cytoreduction and PIC for peritoneal
carcinomatosis from colorectal cancer. The data are
derived from a single-institution experience, spanning
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23 years and include 70 patients who underwent com-
plete (CC-0) or near complete (CC-1) cytoreduction.
Despite a high frequency of recurrent disease (n= 55,
78%), the authors achieved an overall median survival
of 30 months and a 5-year survival of 17%. Twenty-six
patients had at least one reoperation, including a sec-
ond, complete cytoreduction in 18 patients. Fourteen
patients also underwent repeat PIC. Patients who
underwent a second, complete cytoreduction achieved
a median survival of 42 months, and a 5-year survival
approaching 30% was seen in all patients having a
second surgery, regardless of the completeness of cy-
toreduction. In addition, the authors identiﬁed signif-
icant ‘‘failure-related’’ predictors of survival including
the anatomic distribution (localized versus diffuse or
distant) of the recurrence and the time to recurrence.
Assuming the premise that CRS and PIC are indicated
for carcinomatosis in colorectal cancer, the authors
conclude that additional CRS and PIC in selected pa-
tients with recurrencemay result in long-term survival.
Whether this reﬂects the impact of the therapy, or tu-
mor biology that lends itself to subsequent procedures,
is unknown.
Before promoting the repeated use of this highly
morbid treatment for recurrent disease, the appropri-
ate role of CRS and HIPEC in the initial management
of colorectal carcinomatosis remains to be determined.
Whereas historically patients with colorectal carcino-
matosis have had no clinically meaningful treatment
options, there appears now to be two potentially eﬃ-
cacious options—systemic therapy and CRS and HI-
PEC. For a number of reasons, determining the
optimal use of these evolving therapies will not be easy.
Because of the high morbidity, and potential mor-
tality, associated with CRS and HIPEC (mortality
rates of 2–5 % are common), it is not enough to simply
compare the benefits of this treatment to that of sys-
temic therapy. Rather it is the risk-benefit ratio of each
treatment that must be considered and compared.
Furthermore, because CRS and HIPEC employs two
treatment modalities (surgery and chemotherapy), it is
also necessary to consider the individual risk-benefit
ratio of each modality. For example, it is possible that
in the setting of the newer chemotherapy regimens, a
standardized complete cytoreduction may offer the
same benefit as, with significantly less morbidity than,
CRS and HIPEC. Important issues such as this will
only be settled through the completion of an appro-
priately designed and conducted clinical trial.
In addition, the results presented in this manuscript
highlight a number of important CRS and HIPEC-
speciﬁc issues that also require resolution. The ﬁrst
and foremost is that of patient selection. It is notable
that of 156 select patients who underwent attempted
CRS by one of the worlds most experienced perito-
neal surgeons, complete CRS was possible in only 70
(45%), and the true denominator from which these
156 patients were culled is unknown. Furthermore,
despite the accomplishment of a complete cytore-
duction, 78% ultimately developed recurrent disease.
Clearly better-deﬁned criteria for patient selection are
essential before embracing this approach. The au-
thors analysis of the types of recurrence following a
complete cytoreduction provides some guidance for
the development of these criteria.
By evaluating tumor recurrences based on their
anatomic location, Bijelic and colleagues oﬀer a po-
tential rationale for these events that is insightful and
provocative. First, recurrence in the form of distant
metastatic disease raises important questions about
the role of tumor biology (e.g., lymph node status
and primary tumor histology) in patient selection.
Because recovery from CRS and PIC can often delay
the delivery of systemic chemotherapy, it is reason-
able for patients at higher risk of developing extra-
peritoneal disease to receive treatment with
‘‘neoadjuvant’’ systemic therapy based on the newer
chemotherapy regimens. This approach could not
only help identify patients unlikely to beneﬁt from
additional treatment with either CRS or CRS and
PIC, but it may also improve patient outcomes by
treating micrometastatic disease up front, thereby
enhancing the beneﬁt of additional treatments.
Second, for patients with diﬀuse peritoneal recur-
rence, the authors postulate a failure of the chemo-
therapy. It is hard to know exactly what role the
method of intraperitoneal chemotherapy played in this
type of recurrence, as there was use of both
hyperthermic intraoperative and normothermic
perioperative chemotherapy present within the study
population. The concept of a chemotherapy failure
also raises questions about the role of tumor histology
and the potential utility of using DNA or protein
arrays to determine genetic signatures of chemoresis-
tance. In addition, it raises concern as to the potential
impact of prior chemotherapy selecting chemoresistant
tumor cells. This is yet another important question that
can only be answered in the context of a clinical trial.
Third, for patients with localized recurrence the
authors postulate a failure of the surgery. Because all
the patients in this study presumably received the
same initial level of surgical eﬀort, this concept is
intriguing. Unlike unpredictable failures of chemo-
therapy or the progression of undetectable distant
metastases, surgical failures are an opportunity to
identify predictive characteristics of recurrence.
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For example, the Peritoneal Carcinomatosis Index
(PCI) has clearly been established as a predictor of
survival after CRS and PIC for colorectal carcino-
matosis.9,16 Is there a role for PCI (or an alternate
objective measure of tumor burden) in predicting the
different types of recurrences deﬁned by the authors?
Similarly, prior surgical score (PSS) has been shown
to impact the outcome of CRS and HIPEC and may
also play a deﬁnable role in predicting recurrence.6
Finally, the completeness of cytoreduction has clearly
been shown to be one of the most important predic-
tors of success with CRS and HIPEC for any type of
malignancy.17–19 At this time, the clinically signiﬁcant
deﬁnition of a complete cytoreduction for carcino-
matosis from colorectal cancer is controversial. While
a CC-1 may be sufﬁcient for the less aggressive
mucinous neoplasms of the appendix, it may not be
adequate for carcinomatosis from colorectal cancer.
Future analysis of these and other potentially pre-
dictive characteristics of recurrence with respect to
patterns of recurrence and to the patients who do and
do not develop recurrent disease will be essential in
the pursuit of better patient selection.
The authors results with patients who have
undergone second CRS and PIC are truly laudable.
However, given the new era of chemotherapy for
stage IV colorectal cancer, the appropriate role of
CRS, either alone or with PIC, for the initial man-
agement of carcinomatosis remains to be determined.
Early referral to peritoneal surface oncology centers
can facilitate achieving this goal. In addition to
minimizing the number of operations suﬀered by an
individual patient, the experience available at dedi-
cated centers will oﬀer patients the greatest chance at
complete cytoreduction. Furthermore, concentrating
the care of these complex patients in a small number
of high-volume centers will allow a more scientiﬁc
evaluation of the utility of CRS, with and without
PIC, and their appropriate roles (e.g., primary versus
adjuvant therapy) vis-a`-vis systemic chemotherapy.
While there is still a long way to go in the manage-
ment of this devastating disease, at least there now
appears to be some light on the horizon.
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